Cytex Therapeutics, Inc.
biphasic osteochondral implant combining 3D woven textile cartilage phase and 3D printed bone scaffold
- Sector
- Medtech
- Headquarters
- Durham, NC
- Latest Form D
- $125K, Jan 2025
- Total capital
- $19M
- Federal grants
- $18.9M
- 24 awards · 2015–2023
- Rank in peer group#58 of 538
- Private capital raised
- $125K
- 1 Form D · last Jan 2025
- 21 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 2 pending · first 2017
- Rank in peer group#125 of 538
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$125K
- Federal grantHealth and Human S · Phase I · Addressing bone marrow lesions that compromise osteochondral tissue repair$282K
- Federal grantHealth and Human S · Phase II · Cartilage Regeneration with Tunable Inflammation Resistance$578K
- Federal grantHealth and Human S · Phase II · Cartilage Regeneration with Tunable Inflammation Resistance$1.3M
- Federal grantHealth and Human S · Phase II · A Treatment Paradigm for Femoracetabular Impingement (FAI)$849K
- Federal grantHealth and Human S · Phase II · Cartilage Regeneration with Tunable Inflammation Resistance$4.8M
- Federal grantHealth and Human S · Phase II · Cartilage Regeneration with Tunable Inflammation Resistance$1.5M
Show 18 earlier federal awards
- Federal grantHealth and Human S · Phase II · A Treatment Paradigm for Femoracetabular Impingement (FAI)$1.7M
- Federal grantHealth and Human S · Phase II · A Treatment Paradigm for Femoracetabular Impingement (FAI)$830K
- Federal grantHealth and Human S · Phase I · Regenerative rotator cuff repair in a clinically relevant chronic disease model$225K
- Federal grantHealth and Human S · Phase I · Regenerative rotator cuff repair in a clinically relevant chronic disease model$225K
- Federal grantHealth and Human S · Phase I · Evaluating the Safety and Efficacy of Cartilage Regeneration with Tunable Inflammation Resistance$225K
- Federal grantHealth and Human S · Phase I · Evaluating the Safety and Efficacy of Cartilage Regeneration with Tunable Inflammation Resistance$225K
- Federal grantHealth and Human S · Phase II · Cartilage Regeneration with Tunable Inflammation Resistance$709K
- Federal grantHealth and Human S · Phase II · Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model$608K
- Federal grantHealth and Human S · Phase II · Cartilage Regeneration with Tunable Inflammation Resistance$705K
- Federal grantHealth and Human S · Phase II · A crosslinked cartilage-derived matrix for cartilage tissue engineering$1.2M
- Federal grantHealth and Human S · Phase I · A D osteoarthritis model targeting patient populations with high risk genetic polymorphisms$225K
- Federal grantHealth and Human S · Phase I · A 3D osteoarthritis model targeting patient populations with high risk genetic polymorphisms$225K
- Federal grantHealth and Human S · Phase II · Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model$799K
- Federal grantHealth and Human S · Phase II · Hip-Joint Resurfacing with Functional Human Cartilage$188K
- Federal grantHealth and Human S · Phase II · A crosslinked cartilage-derived matrix for cartilage tissue engineering$757K
- Federal grantHealth and Human S · Phase II · Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model$34K
- Federal grantHealth and Human S · Phase II · Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model$191K
- Federal grantHealth and Human S · Phase II · A crosslinked cartilage-derived matrix for cartilage tissue engineering$570K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
112months
from Cytex Therapeutics, Inc.’s first federal award to its first private round.
- First federal award · Aug 2015
- Health and Human S · $570K
- First Form D · Jan 2025
- $125K · 1st Form D
- Awards before first raise
- 24 awards
An association in public records, not a cause or a prediction.
Standing among 538 peers
Line = medianMedtech · Device
- Federal grants#58 · top 11%
- Granted patents#125 · top 23%
- Linked publications#3 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- BRADLEY T ESTESResearcherExecutive Officer, DirectorLinked by 3 patents · $14.4M in grants as PI
- FARSHID T GUILAKResearcherExecutive Officer, DirectorLinked by 1 patent · $1.6M in grants as PI
- CHRISTINE T ESTESExecutive OfficerNamed in SEC Form D filings
- DAVID T NOLANDirectorNamed in SEC Form D filings
- FRANKLIN T MOUTOSExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 6- GrantedArticular Cartilage RepairUSPTOUS 11,109,975
- GrantedArticular Cartilage RepairUSPTOUS 10,940,007
- GrantedArticular Cartilage RepairUSPTOUS 10,022,231
Show all 6 patent records
- Articular Cartilage RepairSep 7, 2021 · US 11,109,975Granted
- Articular Cartilage RepairMar 9, 2021 · US 10,940,007Granted
- Articular Cartilage RepairJul 17, 2018 · US 10,022,231Granted
- Tissue Engineering Methods and CompositionsNov 2, 2017 · Application 15596623Pending
- Tissue Engineering Methods And CompositionsMay 16, 2017 · US 9,649,409Granted
- Articular Cartilage RepairApplication PCTUS2017043290Pending
Recent research by its founders
- Associations of Sleep and Shift Work With Osteoarthritis Risk20262 cites
- A damaging mutation in COL6A3 alters the mechanobiologic response of chondrocytes derived from human induced pluripotent stem cells20260 cites
- Adipose-driven complement-lipid reprogramming controls nociceptive vulnerability in obesity-associated osteoarthritis20260 cites
Related companies, and why
- NASCENT DEVICES, INC.Similar federal contract value in Medtech · null in contracts
- IllumiSonics Inc.Similar federal contract value in Medtech · null in contracts
- Stabili-Teeth Inc.Similar federal contract value in Medtech · null in contracts
- Atlas5D, Inc.Similar federal contract value in Medtech · null in contracts
- BLUE IRIS LABS, INC.Similar federal contract value in Medtech · null in contracts
- Genomenon, Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .